Clinical trials: Cardiovascular Risk Management
- Condition Cardiovascular Risk Management
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Stable Angina (SA), NSTE-ACS (NSTEMI and UA)
Utilisation of Angiox® in European Practice
The objective of this study is to determine utilisation patterns in patients receiving Angiox® in participating European centres.
- Conditions
- Stable Angina (SA), NSTE-ACS (NSTEMI and UA), STEMI (STE-ACS)
- Trial name
- EURO-vision (NCT01011504)
- Where
- 2 sites in France, Germany
- Volunteers
- 2,019 people
- Sponsor
- The Medicines Company
Diabetes Mellitus, Foot Ulcer
Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes
The purpose of this study is to evaluate risk of cancer incidence and mortality associated with the use of REGRANEX (becaplermin) in patients with diabetes who are members of a U.S. Veterans Health Administration.
- Conditions
- Diabetes Mellitus, Foot Ulcer, Diabetic Foot, Diabetic Neuropathies
- Trial name
- NCT01235260
- Testing
- Becaplermin nonusers, Becaplermin users
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Cardiovascular Risk Factors, Cardiovascular Diseases
Management of Cardiovascular Risk Factors
This practical experience should report a retrospective collection of data regarding cardiovascular risk factors of cardiovascular diseases.
- Trial name
- NCT00848380
- Where
- 36 sites in Switzerland
- Volunteers
- 1,492 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cardiac Transplant Failure, Cardiac Transplant Rejection
Outcomes AlloMap Registry: the Long-term Management and Outcomes of Heart Transplant Recipients With AlloMap Testing
The objective of this registry is to observe short and long term clinical outcomes in heart transplant recipients who receive regular AlloMap testing as part of allograft rejection surveillance.
- Conditions
- Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases
- Trial name
- OAR (NCT01833195)
- Where
- 36 sites in United States
- Volunteers
- 2,444 people, healthy volunteers welcome
- Sponsor
- CareDx
Myocarditis, Pericarditis
A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine
The main goal of this study is to describe the clinical course, outcomes and risk factors for myocarditis and pericarditis associated with Moderna vaccination targeting SARS-CoV-2.
- Trial name
- NCT06113692
- Testing
- mRNA-1273
- Where
- 5 sites in Denmark, Norway and 2 more
- Volunteers
- 1,169 people
- Sponsor
- ModernaTX, Inc.